Home What is SMA? Treatments Living with SMA Benefits & Support Mental Health & Wellbeing ▾
Grief and loss Anxiety and worry Fatigue and burnout Isolation and identity Domestic abuse
Community Newborn Screening News & Updates Sell or Swap Shop Business Directory
🇬🇧 UK Community & Information

Living with SMA
in the UK

Independent information, real stories and practical support for people with spinal muscular atrophy, their families and carers across the United Kingdom.

What is SMA? NHS Treatments
I'm looking for information as a…
Parent / Carer Young Person Adult with SMA Newly Diagnosed
SMA in the UK — Key Facts
~700People with SMA in England
1 in 40People carry the SMA gene
3NHS-funded treatments
2017First NHS treatment approved
⚠️ NICE treatment review in progress. Spinraza and Evrysdi remain available via NHS Managed Access Agreements to September 2026 while NICE completes its review.
Where to start

Find what you need

Whether you've just received a diagnosis or you've been living with SMA for years, we have information for every stage.

🧬

Just diagnosed?

Understanding your diagnosis is a lot to take in. Start here with the essentials — what SMA is, the types, and what it means.

Learn about SMA
💊

NHS Treatments

Three disease-modifying treatments are currently funded by the NHS in England. Understand how each works and who is eligible.

View treatments
🏠

Living with SMA

From school and university to work, relationships and getting older — practical guides for every life stage.

Life guides
💰

Benefits & Support

PIP, DLA, Access to Work and Carer's Allowance. Find what financial support you're entitled to — with 2025/26 rates.

Benefits guide
NHS England

Treatments currently funded

Three disease-modifying therapies are available on the NHS for eligible patients. All are under ongoing NICE review.

NHS — Managed Access Agreement

Spinraza

Nusinersen · Biogen

An antisense oligonucleotide that increases SMN protein production. Given by intrathecal injection at a specialist centre. NHS-funded since July 2019.

Route: Intrathecal injection (hospital) Frequency: Loading doses, then 3–4× per year Eligibility: Types 1–3, all ages
NHS — Managed Access Agreement

Evrysdi

Risdiplam · Roche

An oral liquid taken at home daily, increasing SMN protein by targeting the SMN2 gene. NHS-funded since January 2022.

Route: Oral liquid (taken at home) Frequency: Daily Eligibility: 2 months+, Types 1–3
NHS — NICE Recommended

Zolgensma

Onasemnogene abeparvovec · Novartis

A one-time intravenous gene therapy replacing the faulty SMN1 gene. NHS-funded for Type 1 SMA babies up to 12 months. Older children assessed by national MDT.

Route: Single IV infusion (specialist centre) Frequency: Once only Eligibility: Type 1, up to 12 months (NICE); older via MDT

All three treatments are currently available in England

Spinraza and Evrysdi are provided under Managed Access Agreements — NHS funding continues while NICE reviews long-term data. Eligibility is determined by your specialist SMA team.

Spinraza (nusinersen) Evrysdi (risdiplam) Zolgensma (onasemnogene)
Community

Voices from the SMA community

Real stories from people living with SMA across the UK — young people, adults, parents and carers.

👩
Sophie, 24
SMA Type 2 · Leeds · University graduate

"Starting university with SMA felt terrifying. Between DSA, accessible accommodation and Access to Work, I now have a full-time job I love. It took effort but it's absolutely possible."

👨‍👩‍👦
Marcus & Aisha
Parents · Glasgow · Theo, 5, SMA Type 1

"Theo's diagnosis at 8 months was devastating. Starting Zolgensma before he lost more function made an enormous difference. He's at school now and surprising us every day."

👨
James, 38
SMA Type 3 · Bristol · Software engineer

"I stopped walking in my late 20s. Finding the adult SMA community changed everything. People who understand the fatigue, the planning, the grief — and still live fully."

Read more stories
Campaign

Scotland said yes. England is next.

Every baby born in Scotland is tested for SMA within days of birth. A proposal for England is under review. Early treatment — before symptoms — transforms outcomes.

Learn about the campaign
Home › What is SMA?

What is Spinal Muscular Atrophy?

A guide to SMA — what it is, how it's caused, the different types, how it's diagnosed, and how treatment has transformed the outlook.

The basics

Spinal muscular atrophy (SMA) is a rare, inherited neuromuscular condition caused by a fault in a gene called SMN1 (Survival Motor Neuron 1). This gene is responsible for producing a protein called SMN, which motor neurons in the spinal cord need to survive. Without enough SMN protein, these motor neurons progressively deteriorate and die.

As motor neurons are lost, the muscles they control become progressively weaker. This is why SMA primarily affects movement — the ability to walk, sit, hold the head upright, swallow and breathe can all be impacted, depending on severity. SMA does not affect intelligence or cognitive ability.

Significant treatment advances since 2017 have dramatically changed the outlook. Today, with early treatment, many children with SMA are reaching developmental milestones that would have been impossible a decade ago.

Important

SMA does not affect intelligence. People with SMA have the same intellectual capacity as anyone else — the condition affects motor neurons only, not thinking, memory or emotion.

The SMN2 backup gene

Humans have a second, nearly identical gene called SMN2 that can produce a small amount of functional SMN protein — roughly 10% of what SMN1 produces. Everyone with SMA still has at least one copy of SMN2, and most people have between 1 and 4 copies. Having more copies is generally associated with a milder form of SMA. All three NHS-funded treatments work by either increasing SMN protein from the SMN2 gene, or replacing the missing SMN1 gene entirely.

Types of SMA

SMA is classified into types based on age of symptom onset and highest motor milestone achieved without treatment. With modern treatments — especially pre-symptomatic treatment — the boundaries between types are becoming less fixed.

TypeAlso calledOnsetMilestones (untreated)SMN2 copies (typical)
Type 0PrenatalBefore birthRarely survives beyond a few months1
Type 1Werdnig-Hoffmann0–6 monthsCannot sit independently; breathing and swallowing difficulties1–2
Type 2Dubowitz6–18 monthsCan sit; cannot stand or walk unaided3
Type 3Kugelberg-Welander18 months onwardsCan walk; many lose ability to walk in childhood or adulthood3–4
Type 4Adult-onsetAdult lifeAmbulatory; slow progression; often mild symptoms for years4+
Types are guides, not fixed destinies

These categories reflect the typical natural history without treatment. Pre-symptomatic treatment can fundamentally alter the course of the disease — a child identified via newborn screening and treated before symptoms appear may far exceed the milestones historically associated with their SMA type.

Rarer and related forms

The most common form — 5q SMA — is what this site primarily addresses. There are also rarer forms including Kennedy's disease (spinal and bulbar muscular atrophy, affecting adult men), SMARD1 (SMA with respiratory distress), Distal SMA, SMA-LED and pontocerebellar hypoplasia type 1B. If your diagnosis is one of these rarer forms, your specialist neuromuscular team can advise on the specific condition and available management options.

Genetics and inheritance

5q SMA is inherited in an autosomal recessive pattern. A person must inherit a faulty copy of SMN1 from both parents to develop SMA. Someone who inherits just one faulty copy is a carrier — they don't have SMA but could pass it to a child. Around 1 in 40 to 1 in 50 people in the UK carry a faulty SMN1 copy without knowing it. When two carriers have a child together, each pregnancy has a 25% chance of the child having SMA, 50% chance of being a carrier, and 25% chance of having two normal copies. Carrier testing is available — ask your GP for a referral to genetic counselling.

How SMA is diagnosed

SMA is diagnosed through a genetic blood test looking for deletions or mutations in the SMN1 gene. In Scotland, SMA has been included in the newborn bloodspot screening programme since 2021, meaning babies are tested within days of birth — before symptoms appear. A proposal to extend newborn screening to England is currently under review by the UK National Screening Committee. If you have concerns about your child's development, speak to your GP or health visitor. Adults with unexplained progressive weakness should ask for a referral to a neuromuscular specialist — Type 4 SMA is sometimes diagnosed after years of symptoms without a clear cause.

Outlook and prognosis

The outlook for people living with SMA has changed fundamentally since 2017. Three NHS-funded treatments now address the underlying genetic cause. For children treated pre-symptomatically, outcomes have been dramatic — babies who would previously have been severely affected by Type 1 SMA are instead walking and attending school. For people already living with SMA, these treatments can slow progression and, in some cases, lead to improvements in function. SMA remains a lifelong condition requiring ongoing specialist care, but for most people with SMA in the UK today the prognosis is substantially more positive than for previous generations.

Home › Treatments

SMA Treatments in the UK

Three disease-modifying therapies are currently funded by the NHS in England. Here is what each one does, who can access it, and the status of NICE approvals.

⚠️ NICE review in progress — Spinraza and Evrysdi

NICE is conducting a Multi Technology Assessment (MTA) of Spinraza and Evrysdi. The first committee discussion was scheduled for November 2025, with draft recommendations to follow. Both remain available via Managed Access Agreements to September 2026. See latest updates →

NHS — Managed Access Agreement

Spinraza (nusinersen)

Biogen · Antisense oligonucleotide (ASO)
NHS-funded since: July 2019
MAA extended to: September 2026

Spinraza was the first disease-modifying treatment for SMA to reach the NHS. It works by altering how the SMN2 gene's mRNA is processed — specifically helping to include exon 7 in the mRNA transcript — resulting in production of full-length, functional SMN protein. More SMN protein means motor neurons are better supported and disease progresses more slowly.

Spinraza is given by intrathecal injection, directly into the fluid surrounding the spinal cord, by a specialist at an SMA centre. A loading phase involves four injections over the first two months; maintenance injections are then given three to four times per year.

NHS eligibility

Under the current MAA: confirmed diagnosis of SMA Types 1, 2 or 3, or pre-symptomatic SMA with 1–4 SMN2 copies. Not eligible if you've had successful treatment with Zolgensma, or are on permanent ventilation. Your specialist team assesses eligibility and monitors response.

Key clinical evidence

The pivotal ENDEAR trial (Type 1 SMA infants) showed significantly improved motor function and event-free survival versus sham control. The CHERISH trial (Types 2 and 3) showed meaningful motor function improvements. Long-term SHINE extension data shows benefits maintained over multiple years.

NHS — Managed Access Agreement

Evrysdi (risdiplam)

Roche · SMN2 splicing modifier
NHS-funded since: January 2022
MAA extended to: September 2026

Evrysdi works by the same principle as Spinraza — modifying SMN2 mRNA processing to produce more full-length SMN protein — but as a small molecule taken orally. It can be taken as a liquid at home once daily. For many families, the flexibility of home administration versus hospital injections is a significant quality-of-life advantage. Being a systemic therapy, it is distributed throughout the body and may address symptoms beyond the spinal cord.

NHS eligibility

Under the current MAA: people aged 2 months or older with SMA Types 1, 2 or 3, or pre-symptomatic SMA with 1–4 SMN2 copies. Not eligible if Zolgensma has been successfully administered. Eligibility and treatment response is monitored by your SMA specialist team.

Key clinical evidence

The FIREFISH trial (Type 1 infants) and SUNFISH trial (Types 2 and 3) showed clinically meaningful motor function improvements. The RAINBOWFISH study provided data on pre-symptomatic infants. Real-world evidence continues to emerge and is consistent with trial findings.

NHS — NICE Recommended

Zolgensma (onasemnogene abeparvovec)

Novartis · Gene replacement therapy
NHS-funded since: March 2021
List price: £1.79m per dose

Zolgensma is a gene replacement therapy — the most fundamentally different of the three NHS treatments. Rather than modifying how SMN2 works, it delivers a functional copy of SMN1 directly into cells via an adeno-associated viral vector (AAV9). A single intravenous infusion is given at one of four national SMA treatment centres in England.

NHS eligibility

NICE recommends Zolgensma for babies with SMA Type 1 up to 12 months old, or pre-symptomatic babies up to 12 months with confirmed 5q SMA and up to 3 SMN2 copies. A National Multidisciplinary Team (NMDT) can also consider Zolgensma for older children with Type 1 within the EMA marketing authorisation (under 21 kg), reviewed case by case.

Liver monitoring required

Some children treated with Zolgensma have developed liver enzyme elevations. Strict monitoring protocols are in place. Your clinical team will explain the monitoring schedule before treatment begins.

Key clinical evidence

The STR1VE-US Phase 3 trial and SPR1NT trial (pre-symptomatic infants) showed striking outcomes — particularly in babies treated before or shortly after symptom onset. Long-term follow-up from the START trial showed motor function improvements maintained at 6+ years.

Research pipeline

Treatments on the horizon

FDA-Approved (US only) — Not yet available in UK

Itvisma (intrathecal onasemnogene)

Novartis · Intrathecal gene therapy

An intrathecal formulation of onasemnogene abeparvovec that delivers the SMN1 gene directly into the cerebrospinal fluid via lumbar puncture, rather than intravenously. This allows a much lower dose and is designed for older children, teenagers and adults who are too large for intravenous Zolgensma. Itvisma received FDA approval in the United States in November 2025, based on positive data from the STEER Phase 3 trial.

UK status: Itvisma has not been reviewed by NICE or authorised by the MHRA for use in the UK. There is no NHS commissioning of this treatment. Novartis would need to submit for MHRA marketing authorisation and a NICE appraisal before it could become available on the NHS.

Clinical trials ongoing

Apitegromab & next-generation approaches

Scholar Rock & others · Muscle-targeted therapies

Apitegromab is a myostatin inhibitor studied as an add-on therapy for people with Types 2 and 3 SMA already on SMN-targeting treatment. Rather than increasing SMN protein, it works by blocking myostatin — a protein that limits muscle growth and strength. Phase 2 data showed promise; a Phase 3 SAPPHIRE trial has been completed. No UK approval has been granted. Other pipeline areas include neuroprotective agents and combination therapy approaches.

Home › Living with SMA

Living with SMA

Practical guides for every life stage — from childhood through school, university, work and adulthood, with information specific to the UK.

If your child has just been diagnosed

Receiving an SMA diagnosis for your child is deeply shocking, whatever the type. It's completely normal to feel overwhelmed, frightened, and to grieve. These feelings don't mean you're failing — they mean you love your child.

The most important early step is to be referred to a specialist neuromuscular centre. Your child's care will be led by a multidisciplinary team including a paediatrician with neuromuscular expertise, a physiotherapist, respiratory specialist and dietitian.

Questions to ask at your first specialist appointment
  • Which type of SMA does my child have, and how many SMN2 copies?
  • Which treatments is my child eligible for?
  • How quickly should we start treatment?
  • What monitoring will be in place?
  • Are there clinical trials my child might be eligible for?

If you've just been diagnosed as an adult

Adult-onset SMA (Types 3 or 4) is sometimes diagnosed after years of unexplained weakness — making the eventual diagnosis a mix of relief and shock. You may have been living with symptoms for a long time without knowing their cause.

Ask your GP for a referral to a neuromuscular specialist. Regional adult neuromuscular services exist across England. Your specialist will assess whether NHS-funded treatment is appropriate for you.

Connecting with the SMA community — via SMA UK, TreatSMA or online groups — can be profoundly helpful. Meeting others who genuinely understand your experience makes a real difference.

Respiratory care

Many children with SMA — particularly Types 1 and 2 — need breathing support. This may involve non-invasive ventilation (NIV) during sleep, using BiPAP or CPAP, and/or a cough assist device to help clear secretions. Your child's respiratory team will assess regularly and guide you on home equipment use.

Physiotherapy and scoliosis

Regular physiotherapy helps maintain joint flexibility and support respiratory function. Many children with SMA develop scoliosis. This is monitored regularly and managed with seating, spinal bracing, or in some cases surgery. Maintaining good posture and positioning from an early age is an important part of long-term spinal health.

Starting school

Most children with SMA attend mainstream school with appropriate support. An Education, Health and Care Plan (EHCP) from your local authority sets out the support your child needs. Start the EHCP application process early — ideally before your child starts school. Your school should provide accessible toileting, appropriate seating, support for personal care, and any technological aids needed.

Nutrition

Children with SMA may have difficulty chewing or swallowing (dysphagia) and may need adapted food textures or supplemental feeding via a gastrostomy tube. A specialist dietitian and speech and language therapist will advise on feeding. Maintaining a healthy weight is important — both excessive and insufficient weight affect function and respiratory health.

Exams and access arrangements

Exam access arrangements allow students to access exams on a level playing field. Common arrangements for students with SMA include extra time (typically 25%), rest breaks, use of a scribe or word processor, and small group or separate rooms. Arrangements must be applied for through your school's SENCO. Document the need well in advance — don't wait until exam season.

Transition to adult services

Moving from children's to adult health and social care services — called transition — typically happens between 16 and 18. Your clinical team should begin transition planning by around age 14–16. Transition also involves moving from Children's DLA to a PIP claim at 16 — start the PIP application well before your 16th birthday to avoid a gap in payments.

Identity and mental health

Adolescence is already a time of significant identity formation. Growing up with a disability adds additional complexity — questions about body image, relationships and independence are real and valid. CAMHS (Child and Adolescent Mental Health Services) can provide support. Peer support from others with SMA, which many young people find invaluable, is available through SMA UK and TreatSMA.

Assistive technology

Assistive technology has transformed independence for many teenagers with SMA — from eye-gaze communication systems to voice control software, adapted gaming controllers, and smart home technology. Your occupational therapist can assess your needs and help source the right equipment, much of which is available through NHS provision.

University with SMA

University is absolutely achievable with SMA, with the right support in place. Contact disability services at any university you're considering before applying. Key areas to plan:

  • Disabled Students' Allowance (DSA): Government funding for non-medical helpers, specialist equipment and travel. Apply via Student Finance England as early as possible.
  • Accessible accommodation: Confirm in writing that allocated accommodation meets your specific needs before accepting.
  • Personal Assistants: May be funded through your local authority's social care package or DSA. Arrange before arrival.
  • Healthcare continuity: Register with a local GP near university and contact your specialist centre about continuing SMA treatment during term.

Access to Work

Access to Work is a government grant — not a loan — helping disabled people start or stay in paid work. It is one of the most valuable and underused benefits for working-age people with SMA.

  • Maximum award: up to £69,260 per year (2025/26)
  • Can fund: personal assistants at work, adapted equipment, taxi travel, mental health support
  • Not means-tested — not affected by salary
  • Available to employed and self-employed people
Apply early

Access to Work can take several months to process. Apply as early as possible — ideally before starting a new role. You cannot backdate the grant.

Managing fatigue

Fatigue is one of the most significant and often invisible aspects of living with SMA as an adult — caused by the physical effort of performing tasks with weaker muscles, disrupted sleep from respiratory issues, and the cognitive load of managing a complex condition. Pacing strategies, energy-saving equipment, and occupational therapy can all help. When fatigue significantly impacts your life, ask your GP for a referral.

Housing adaptations

The Disabled Facilities Grant (DFG) from your local authority funds essential adaptations — wet rooms, widened doorways, stairlifts, hoists and ramps. Up to £30,000 in England (means-tested for adults in their own home; not for children). Apply through your local council's housing or adult social care team. Waiting times can be long — apply early.

Personal Assistants and direct payments

If you're assessed as needing social care support, you may be able to receive a direct payment from your local authority to employ your own personal assistant rather than using council-arranged care. This gives you much more control over who supports you, when and how. Request a care needs assessment from adult social care to find out if you're eligible.

Relationships, sex and parenthood

People with SMA have relationships, have sex, and become parents. Specialist relationship or sexual health counsellors can provide tailored guidance. If considering having children, genetic counselling is available to discuss inheritance risks and testing options. Pregnancy with SMA requires specialist joint obstetric and neuromuscular care — speak to your specialist team early if planning to conceive.

Carer's Assessment

As a carer, you're entitled to a Carer's Assessment from your local authority — an assessment of your own needs, health and wellbeing, separate from the person you care for. You may be eligible for local support services, respite care or financial support. Contact adult social care at your local council to request an assessment.

Carer's Allowance

Carer's Allowance (£81.90/week, 2025/26) is available if you provide at least 35 hours of care per week for someone receiving PIP daily living component or DLA care at middle or higher rate. Note: there is an earnings limit (£151 net per week). Even if you're over pension age and can't receive Carer's Allowance, you may still be eligible for Carer's Credit to protect your National Insurance record.

Looking after yourself

Caring for a family member with a complex condition is demanding — physically, emotionally and mentally. Carer burnout is real. Acknowledging your own needs is not selfish — it is essential. Carers UK, the Carers Trust and SMA UK all have resources for carers. Respite care gives you a break and should be part of your care package.

Supporting siblings

Brothers and sisters of children with SMA can sometimes feel overlooked as family life revolves around medical needs. Sibling support services exist — Sibs provides information and support specifically for siblings of disabled people. Open, age-appropriate conversation with siblings about SMA helps them feel included and understand what's happening.

Home › Benefits & Support

Benefits & Financial Support

A guide to main financial support available to people with SMA and their carers in the UK. Rates shown are 2025/26.

Get expert advice

This guide gives a general overview. Your specific entitlements depend on individual circumstances. Organisations like Citizens Advice, Turn2Us and Disability Rights UK offer free, confidential advice. Always seek professional benefits advice before making decisions.

Disability Living Allowance (DLA) — for children

Up to £184.30/week

DLA is for disabled children under 16 with two components: care component (help with personal care) and mobility component (help getting around). Highest care rate: £108.55/week; highest mobility rate: £75.75/week. Most children with SMA needing daily care will qualify.

Not means-testedUnder 16s onlyEnables Carer's Allowance

Personal Independence Payment (PIP)

Up to £184.30/week

PIP replaces DLA for disabled people aged 16–64. Has a daily living component and mobility component. Enhanced daily living: £108.55/week; standard: £72.65/week. Enhanced mobility: £75.75/week; standard: £28.70/week. Assessed on functional ability, not diagnosis — ensure your assessment reflects your worst days.

Not means-testedAge 16+Assessment required

Carer's Allowance

£81.90/week

For people caring for someone with a disability for at least 35 hours per week. The person you care for must receive PIP daily living (either rate) or DLA care at middle or higher rate. Earnings limit: £151 net per week. Note: cannot be received alongside a full State Pension, though Carer's Credit remains available to protect your NI record.

Earnings limit appliesProtects NI record

Access to Work

Up to £69,260/year

A government grant — not a loan — helping disabled people start or stay in paid work. Can fund: personal assistants at work, adapted equipment, taxi fares to work where public transport is inaccessible, and mental health support. Available for employed and self-employed people. Not means-tested. Apply via gov.uk — process can take several months so apply as early as possible.

Not means-testedEmployed & self-employed

Universal Credit (LCWRA element)

Variable — income-related

If unable to work due to SMA, you may qualify for the Limited Capability for Work-Related Activity (LCWRA) element of Universal Credit. This adds a significant amount to your UC payment and means you have no work-related requirements. UC is means-tested — complex interactions exist with other benefits. Take advice before claiming or changing existing benefit arrangements.

Means-testedWorking-age adults

Disabled Facilities Grant (DFG)

Up to £30,000

Local authorities must provide DFG for essential home adaptations — step-free access, level access showers, widened doorways, hoists, ramps. Means-tested for adults in their own home; not for children. Apply through your local council. An OT assessment determines what adaptations are needed. Waiting times can be long — apply early.

Means-tested for adultsNot means-tested for children

Where to get help

Citizens Advice

Free, confidential advice on benefits, debt and housing. Search for your local branch or visit citizensadvice.org.uk

Turn2Us

Free benefits calculator and grants search at turn2us.org.uk — identifies all benefits you may be entitled to.

Disability Rights UK

Comprehensive guides on disability benefits and rights. Factsheets on PIP, DLA and employment at disabilityrightsuk.org

SMA UK / TreatSMA

SMA-specific advice and signposting. Support teams understand the specific needs of the SMA community.

Wellbeing › Physio with Marion

Physio with Marion

A series of specialist physiotherapy webinars for people living with SMA — covering exercises, techniques and practical advice.

Loading videos…

Home › Mental Health & Wellbeing

Mental Health & Wellbeing

Living with SMA — or caring for someone who does — has a genuine psychological impact. This is often underacknowledged, and there is no shame in seeking support.

A Guide to the 2017 International Standards of Care for SMA

Standards of Care

A family-friendly guide to the care and support that people with SMA should expect — written in plain language for patients and families.

Family Friendly Version
TreatSMA Hospitalisation Care Form

Hospitalisation Care Form

Download the SMA Hospitalisation Care Form — essential information to share with hospital teams to ensure safe, informed care during admission.

Download PDF
Physio with Marion

Physio with Marion

A series of webinars with specialist physiotherapist Marion, covering exercises, techniques and advice tailored for people living with SMA.

Watch webinars
Official Standards of Care — Part 1

Diagnosis and management of spinal muscular atrophy: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

Official Standards of Care — Part 2

Diagnosis and management of spinal muscular atrophy: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

Grief and loss

Grief is a normal and legitimate response to SMA — for people with the condition and for those who love them. This includes grief at diagnosis, grief as abilities change over time, and grief for the life you imagined. These feelings deserve to be acknowledged, not suppressed.

The grief associated with a progressive condition is sometimes described as "chronic sorrow" — not a one-time event, but a recurring experience triggered by life transitions, medical appointments, or watching others reach milestones. This is normal. It doesn't mean you aren't coping.

Anxiety and worry

Anxiety is common among people with SMA and their families. Concerns about disease progression, the outcome of the NICE treatment review, how to navigate systems, and what the future holds can all generate significant anxiety.

Practical strategies include staying informed from reliable sources, talking to your clinical team when worried, and using relaxation or mindfulness techniques. When anxiety significantly impacts daily life, talking therapies can be very effective — ask your GP for a referral.

Fatigue and burnout

Both physical fatigue (from the increased effort of living with weaker muscles) and mental fatigue (from navigating complex systems and the cognitive load of managing a complex condition) are real and valid. Burnout is also common in carers.

Don't wait until crisis point. Regular respite, social connection and professional support — whether through a GP, therapist or peer support network — can make a significant difference.

Isolation and identity

SMA is rare — most people will never meet someone else with the condition in daily life. This can lead to genuine loneliness and a sense that no one else truly understands. Online and in-person communities of people with SMA can be profoundly valuable.

For adults and teenagers especially, questions of identity are important. SMA is one part of who you are, not the whole story.

Mental health support in the UK

NHS Talking Therapies

Free NHS psychological therapies for adults 16+. You can self-refer — no GP referral needed. Search for your local service on the NHS website.

Rareminds

Specialist counselling for people with rare diseases and their families. Practitioners understand the specific psychological impact of rare conditions.

CAMHS

NHS Child and Adolescent Mental Health Services for under-18s. Your GP can make a referral. Waiting times vary by area.

Carers UK

Support and advice specifically for carers, including emotional support and signposting to local services. carersuk.org

Mind

Information, support and local services for mental health issues. mind.org.uk

Samaritans — 24/7

If you're in crisis or struggling, Samaritans are available 24 hours a day. Call 116 123 (free from any phone). Email jo@samaritans.org

Domestic Abuse

Domestic abuse does not discriminate — people across genders, sexualities, races, abilities and more can be victims of domestic abuse. Many topics highlighted in this area are common tactics used by abusers, and everyone is vulnerable to them. However, we focus specifically on the vulnerabilities of unpaid carers and the difficulties faced when trying to leave abusive relationships.

This content has been written through a combination of research and speaking to unpaid carers with lived experience of domestic abuse.

Domestic abuse support in the UK

National Domestic Abuse Helpline — 24/7

Run by Refuge, this is the primary helpline for anyone experiencing domestic abuse in England. Free, confidential and available around the clock. Call 0808 2000 247 or use the online chat at nationaldahelpline.org.uk

Women's Aid

National charity providing life-saving services and support to women and children experiencing domestic abuse. Offers a live chat service, email support, and the Survivor's Handbook with practical guidance. womensaid.org.uk

Men's Advice Line

Confidential helpline for male victims of domestic abuse, offering emotional support, safety planning and signposting to specialist local services. Call 0808 801 0327 (free). mensadviceline.org.uk

ManKind Initiative

National charity supporting male victims of domestic abuse and their children. Provides a helpline, online resources and referrals to local refuge and support services for men. Call 01823 334244. mankind.org.uk

National Centre for Domestic Violence

Free, fast emergency injunction service helping victims obtain a non-molestation or occupation order to stop an abuser approaching or contacting them. Legal protection with no income or means test. Call 0800 970 2070. ncdv.org.uk

Rights of Women

Feminist legal charity offering free, confidential legal advice to women on domestic abuse, coercive control, financial abuse, immigration and family law. Run by qualified solicitors. Call 020 7251 6577. rightsofwomen.org.uk

Surviving Economic Abuse

UK charity dedicated to raising awareness of economic abuse — where an abuser controls finances, blocks access to money, or sabotages employment. Provides resources, tools and specialist support for those affected. survivingeconomicabuse.org

Galop — LGBT+ Abuse Helpline

The UK's LGBT+ anti-abuse charity, providing specialist support to LGBT+ people experiencing domestic abuse, hate crime or sexual violence. Staff understand the specific barriers LGBT+ survivors face. Call 0800 999 5428. galop.org.uk

Victim Support

Independent charity providing free, confidential emotional and practical support to victims and witnesses of all crimes, including domestic abuse — regardless of whether the crime has been reported to police. Call 0808 168 9111. victimsupport.org.uk

Carers UK

National charity providing information, advice and peer support specifically for unpaid carers. Their helpline can advise carers on their rights and local support if they are in or escaping an abusive situation. Call 0808 808 7777. carersuk.org

Carers Trust

Works to improve support and recognition for unpaid carers across the UK through a network of local carers centres. Can help carers access practical support, respite and tailored advice in their area. Call 0300 772 9600. carers.org

Samaritans — 24/7

Available around the clock for anyone in emotional distress, including those in or escaping abusive situations. Completely confidential — you don't have to be suicidal to call. Call 116 123 (free, any phone). samaritans.org

Home › Community

Community

Stories, discussions and connections from across the SMA community in the UK.

Stories

Voices from our community

TreatSMA Community group cover

TreatSMA Community

Our main community group — share stories, ask questions and connect with SMA families across the UK.

Join group
TreatSMA Adults group cover

TreatSMA Adults

A dedicated group for adults living with or affected by SMA — share experiences, advice and support.

Join group
SMAll talk group cover

SMAll talk

A friendly space for anyone with or affected by SMA to post questions, chat and find support.

Join group
👩
Sophie, 24
SMA Type 2 · Leeds

"Starting university with SMA felt terrifying. Between DSA, accessible accommodation and Access to Work, I now have a full-time marketing job I love. It took effort but it's absolutely possible."

👨‍👩‍👦
Marcus & Aisha
Parents · Glasgow · Theo, 5, Type 1

"Theo's diagnosis at 8 months was devastating. Starting Zolgensma before he lost more function made an enormous difference. He's at school now and surprising us every day."

👨
James, 38
SMA Type 3 · Bristol

"I stopped walking in my late 20s. Finding the adult SMA community changed everything. People who understand the fatigue, the planning, the grief — and still live fully."

👧
Riya, 16
SMA Type 2 · Birmingham

"My school was brilliant when we got my exam access arrangements in place — extra time and a laptop. My GCSEs were better than I expected. Sixth form feels much less daunting now."

👩‍🦳
Donna, 52
Carer · Manchester · Son Callum, 21

"Transitioning Callum to university was the hardest thing we've done as a family. But seeing him thrive there, with the right support, made it worth every difficult conversation."

👨‍🏫
Peter, 55
SMA Type 4 · Edinburgh · Teacher

"I was diagnosed at 42 after years of unexplained weakness. Type 4 SMA is rare and often unrecognised. Having a name for it — and a community — finally made sense of my whole life."

Discussion

Community conversations

A selection of recent discussions. A safe space for questions and shared experience.

DSA application — how long did yours take?

Just starting my first year at university. Applied for DSA 6 weeks ago and still waiting. Is this normal?

24 replies3 days ago

Switching from Spinraza to Evrysdi — anyone done this?

My consultant has suggested discussing switching. Interested to hear experiences, especially around the transition period.

41 replies1 week ago

DFG waiting times — is 18 months normal?

We applied for a Disabled Facilities Grant for a wet room in November. Our council says 18 months. Is that typical?

17 replies2 weeks ago

Telling your employer about SMA — how much did you share?

Starting a new job next month. Do I disclose before I start? During the Access to Work application? Nervous about how it'll be received.

33 replies3 weeks ago

NICE review — what does the MAA extension to September 2026 mean for patients on treatment?

Anxious about the ongoing NICE review of Spinraza and Evrysdi. Can someone explain what the MAA extension actually means in practice?

58 replies1 month ago
Home › Newborn Screening

Newborn Screening for SMA

The case for universal newborn SMA screening across the UK — and where the four nations currently stand.

Why newborn screening matters

Motor neurons lost to SMA cannot be replaced. Once they're gone, they're gone. This is the core argument for newborn screening: if we can identify SMA before symptoms appear, treatment can begin before significant motor neuron loss — and outcomes are dramatically better.

Clinical trials in pre-symptomatic infants — including the NURTURE study (Spinraza) and SPR1NT study (Zolgensma) — have shown outcomes almost indistinguishable from unaffected peers. Children who would otherwise have been profoundly affected by Type 1 SMA are instead walking and attending school.

Newborn bloodspot screening — the "heel prick" test already given to every UK baby — can be extended to include SMA by adding an analysis to the existing sample taken at 5 days of age.

Scotland said yes. England is reviewing.

Scotland added SMA to its newborn bloodspot screening programme in 2021 — every baby born in Scotland is now tested for SMA within days of birth.

In England, a formal proposal for SMA newborn screening was submitted to the UK National Screening Committee (UK NSC) in early 2026. The UK NSC will consider the evidence and make a recommendation to ministers. If approved, implementation would then need to be planned and funded.

Wales and Northern Ireland are awaiting the outcome of the England review, as policy in these nations generally follows UK NSC recommendations.

UK nations

Current status by nation

🏴󠁧󠁢󠁳󠁣󠁴󠁿

Scotland

✓ Active since 2021

All babies born in Scotland are screened for SMA as part of the newborn bloodspot programme.

🏴󠁧󠁢󠁥󠁮󠁧󠁿

England

Under review

Proposal submitted to UK NSC in early 2026. Review and recommendation pending.

🏴󠁧󠁢󠁷󠁬󠁳󠁿

Wales

Pending

Awaiting UK NSC recommendation and its application to Welsh NHS policy.

🇬🇧

Northern Ireland

Pending

Awaiting UK NSC recommendation and its application to Northern Ireland policy.

Every baby in the UK deserves this chance

SMA screening costs very little per baby tested. Early treatment costs far less than the lifelong support needed when SMA progresses untreated. Most importantly — every baby diagnosed early has a chance at a life transformed.

Follow campaign progress
Home › News & Updates

News & Updates

The latest on SMA treatments, research, policy and community news in the UK.

Content accuracy

We aim to ensure all content is accurate and evidence-based. Treatment status information reflects the position as of early 2026. If you have concerns about accuracy, please contact us.

Latest

Treatment & Policy News

Loading news…

Community

Sell or Swap Shop

A community marketplace for SMA families. Buy, sell, swap or give away equipment, clothing, books and more.

Loading listings…

Community

Business Directory

Find SMA-owned businesses and services supporting the SMA community across the UK.

Loading directory…

Add your Business

Contact details shown publicly on your listing. All fields optional except your private email below.

Remove a Listing

Enter your removal code to remove your listing from the directory.

Business Details

List an Item

£

You'll receive a removal code by email so you can remove your listing when it's no longer available.

Contact Seller

Clicking the button below will open your email app with the seller's address pre-filled so you can get in touch directly.

Remove My Listing

Enter the removal code that was emailed to you when you posted your listing.